Alzheimer’s disease starts long before anyone notices it. The changes in the brain that eventually show up as memory lapses, confusion or personality shifts can…
Key Points Alzamend Neuro has regained compliance with Nasdaq’s continued-listing requirements. The company reported stockholders’ equity of approximately $5.8 million as of July 31, 2026,…
Biogen (NASDAQ: BIIB) is using AAIC 2026 to showcase the depth of its Alzheimer’s portfolio, including new Phase 2 data for its tau‑targeting antisense drug…
January 05, 2026
MapLight Therapeutics’ ML-007C/MA Earns FDA Fast Track Designation for Alzheimer’s Disease Psychosis
MapLight Therapeutics (Nasdaq: MPLT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational therapy ML-007C/MA for the…